Ridge Expansion by Osseodensification Simultaneously With Implant Placement in Narrow Alveolar Ridges
NCT ID: NCT03592381
Last Updated: 2018-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2018-08-30
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Interventions:
I. Pre-operative phase:
Clinical Examination:
1. Visual examination, palpation and inspection of the entire oral and Para-oral tissues.
2. Preoperative alginate impressions for both the maxillary and the mandibular Ridges.
3. Full mouth scaling and root planing, followed by oral hygiene instructions.
4. The Bucco-Lingual/Palatal alveolar ridge width measurement at site of interest using a bone caliper.
5. Study casts will be made in order to properly evaluate the inter-arch space, occlusion type and direction of forces in regard to the site of the future implant.
Radiographic Examination:
1. A panoramic radiograph for screening purposes:
* Estimating the residual bone height.
* Verify the absence of any pathology in the bone.
2. Cone beam computed Tomography (CBCT) for Diagnostic purposes:
* Detect the Bucco-lingual/palatal alveolar ridge width and height at the site of interest.
* Detect approximation to any anatomical boundaries (e.g.mental foramen, maxillary sinus floor.)
* Detect bone type.
II. Surgical phase:
All procedures will be done under strictly aseptic conditions
1. Patients will be anesthetized at the surgical site by the appropriate method using Articaine Hydrochloride 4%.
2. At the site a horizontal incision will be created, extending the entire length of the edentulous area, extending one tooth mesial and distal. Anterior and/or posterior vertical releasing incision will be made as needed.
3. Full thickness mucoperiosteal flap will be raised with complete exposure of the alveolar bone.
4. Bone width will be reconfirmed intrasurgically using a bone caliper. Measurements will be taken at around 1 mm below the crestal margin, to the nearest 0.5mm. Alveolar ridge width measurements will be repeated at second stage surgery.
5. A.For the intervention:
1. Drilling of bone will commence using the Pilot Drill to the desired depth (Drill speed 800-1500 rpm with copious irrigation).
2. Osseodensification drilling will begin with the narrowest Densah Bur. (Counterclockwise drill speed 800-1500 rpm with copious irrigation). If when running the bur into the osteotomy a feeling of haptic feedback of pushing up and out of the osteotomy, repetitively lifting off and reapplying pressure with a pumping motion will be applied until the desired depth is reached.
3. Densah Burs will be used sequentially in small increments. As the bur diameter increases, the bone will slowly expand to the final diameter.
4. The osteotomy final preparation diameter would be an average diameter that measures 0.5-0.8 mm smaller than the implant average diameter in soft bone, and In hard bone, diameter that measures 0.2-0.5 mm smaller than the implant average diameter.
5. Implant placement using the drill motor initially, then Finishing placement of the implant to depth with a torque-indicating wrench.
6. If \< 1mm of buccal bone thickness has resulted after osseodensification, bone grafting post implant placement and complete implant coverage will be considered
5.B.For the control:
1. A bone crestal incision will be created, using the piezo-electric surgical tips. The cut will be done through the cortical bone to reach the trabecular bone.
2. One/two vertical cuts will be created by piezo-drill as needed connecting, to the crestal cut.
3. Conventional Drills will be used for osteotomy preparation by wedging it between the two plates of bone.
4. The implant with the proper length and diameter will be gradually engaged to separate the buccal and Lingual/palatal bone until full seating is achieved.
6\. Cover screws will be placed on the implants. 7.Closure of the flap will be done by interrupted sutures using 4-0 resorbable suture materials.
III. Post-operative phase:
Post-operative instructions and medication:
Patient is recommended to:
1. Maintain a soft diet to avoid trauma to the surgical site.
2. Place a cold compress superficially on the skin overlying the surgical site immediately. Apply for 30 minutes, then off for 20-30 minutes. This should be done on a near continuous basis (or as much as possible) for the first 48 hours.
3. Maintain Oral hygiene but avoid surgical site for the first 4 days after surgery.
4. Medications (Ferrigno et al. 2005)( Garcez-Filho et al.2015) • Augmentin\* (1g tablets) will be prescribed twice daily for 5 days to avoid possibility of infection.
• Ibuprofen\*\* 600mg four times daily for one week.
• Voltarene\*\*\* (75 mg injection I.M.) will be used in case of severe pain, as a rescue.
• Hexitol\*\*\*\* 0.12% chlorhexidine mouth rinse for 2 weeks.
5. Sutures will be removed after 2 weeks
6. Final restoration will be completed after 6 months
* Augmentin 1g. Medical union pharmaceuticals co. Abu Sultan, Ismailia, Egypt. \*\*BRUFEN 600 (Ibuprofen 600 mg). Kahira Pharm. \& Chem. Ind. Co., Under licence from: Abbott Laboratories.
* Voltarene® 75mg/3ml (IM). Diclofenac natrium. NOVARTIS PHARMA. S.A.E.
* Hexitol Chlorhexidine Hcl 125 mg / 100 ml. Arab Drug Company (ADCO).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ridge expansion by osseodensification
Ridge expansion and osteotomy drilling by osseodensification in conjunction with simultaneous implant placement in narrow ridges.
Ridge Expansion by ossedensification
Osseodensification is a new concept facilitated by Densah® Burs which are a multi- fluted osteotome like drilling instrumentsThe idea behind the technique is using a non-subtractive drilling mode that preserves bone and increases its density along the osteotomy walls instead of cutting it away (Huwais and Meyer 2015)
Ridge expansion by ridge splitting
Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
ridge expansion by ridge splitting
using the piezotome,Piezoelectric ridge splitting allows exact, clean, and smooth even curved cutting of the bone tissue, with proper visibility.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ridge Expansion by ossedensification
Osseodensification is a new concept facilitated by Densah® Burs which are a multi- fluted osteotome like drilling instrumentsThe idea behind the technique is using a non-subtractive drilling mode that preserves bone and increases its density along the osteotomy walls instead of cutting it away (Huwais and Meyer 2015)
ridge expansion by ridge splitting
using the piezotome,Piezoelectric ridge splitting allows exact, clean, and smooth even curved cutting of the bone tissue, with proper visibility.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients having a Bucco-lingual/palatal width of the edentulous alveolar ridge less than 6 mm with a minimum of 3mm residual bone width.
3. Patients having at least 11 mm residual bone height at the proposed edentulous area.
4. The recipient bed of the implant should be free from any pathological conditions.
5. No history of diagnosed bone disease or medication known to affect bone metabolism.
6. Patients who are cooperative, motivated, and hygiene conscious.
Exclusion Criteria
2. Patients with insufficient vertical inter-arch space, upon centric occlusion, to accommodate the available restorative components.
3. Patients who have any systemic condition that may contraindicate implant therapy.
4. Patients with modifying habits affecting osteointegration for example, smoking and alcoholism.
5. Patients with parafunctional habits that can overload the implant, such as bruxism and clenching.
6. Patients with impractical expectations about the esthetic outcome of implant therapy.
7. Patients in the growth stage with mixed dentition.
8. Patients with a history of drug abuse.
9. Patients with a history of psychiatric disorder.
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Radwa Abdelhamid ElMaghrabi
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Radwa A ElMaghrabi, BSC
Role: PRINCIPAL_INVESTIGATOR
Cairo University
Amr zahran, PHD
Role: STUDY_DIRECTOR
Cairo University
Ahmed Al barbary, PHD
Role: STUDY_CHAIR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Faculty of Dentistry -Cairo University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
radwa a elmaghrabi, bsc
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14422015497758
Identifier Type: -
Identifier Source: org_study_id